In Vivo Estrogen Regulation of Epidermal Growth Factor Receptor in Human Endometrium
Judith H. McBean,
John R. Brumsted and
William S. Stirewalt
Department of Obstetrics and Gynecology, Division of Reproductive
Endocrinology and Infertility (J.H.M., J.R.B.), and the Department of
Obstetrics and Gynecology, Division of Research (W.S.S.), University of
Vermont College of Medicine, Burlington, Vermont 05401
Address all correspondence and requests for reprints to: Judith H. McBean, M.D., Department of Obstetrics and Gynecology, Division of Reproductive Endocrinology and Infertility, University of Vermont College of Medicine, Burlington, Vermont 05401.
The effects of estrogen and progesterone on the expression ofepidermal
growth factor receptor (EGFR) in human endometriumwere studied in
hypogonadal women under conditions that simulateda normal menstrual
cycle. All women received the same regimenof estrogen and progesterone
and underwent serial biopsies.In one group of women (group I), a
biopsy was obtained beforereceiving estrogen (CD0) and after 11 days
(CD11) of estrogenreplacement. A second group of women was biopsied on
CD11 andCD21 to assess the combined effects of progesterone and
estrogen(group II). Immunohistochemistry was used to test for the
presenceof EGFR, and a ribonuclease protection assay was used to
assessthe amounts of EGFR messenger ribonucleic acid (RNA) relativeto
ribosomal RNA in the tissue. In group I, a significant increasein EGFR
messenger RNA from CD0 to CD11 was observed. A similarincrease was
observed to occur between CD11 and CD21 in groupII. Immunostaining for
EGFR was absent in all CD0 biopsies,but was present in all
estrogen-exposed endometrium. No differencein immunostaining was noted
between CD11 and CD21. We concludethat estrogen stimulates the
synthesis of EGFR in human endometriumand that progesterone does not
appear to modulate this effect.The examination of other parameters in
hormone-replaced hypogonadalsubjects will be valuable in understanding
the complex physiologicalregulation of the human endometrium.
This article has been cited by other articles:
A. T. Baron, E. M. Cora, J. M. Lafky, C. H. Boardman, M. C. Buenafe, A. Rademaker, D. Liu, D. A. Fishman, K. C. Podratz, and N. J. Maihle Soluble Epidermal Growth Factor Receptor (sEGFR/sErbB1) as a Potential Risk, Screening, and Diagnostic Serum Biomarker of Epithelial Ovarian Cancer
Cancer Epidemiol. Biomarkers Prev.,
February 1, 2003;
12(2):
103 - 113.
[Abstract][Full Text][PDF]
C. J. Lockwood, G. Krikun, A. B. C. Koo, S. Kadner, and F. Schatz Differential Effects of Thrombin and Hypoxia on Endometrial Stromal and Glandular Epithelial Cell Vascular Endothelial Growth Factor Expression
J. Clin. Endocrinol. Metab.,
September 1, 2002;
87(9):
4280 - 4286.
[Abstract][Full Text][PDF]
A. T. Baron, J. M. Lafky, V. J. Suman, D. W. Hillman, M. C. Buenafe, C. H. Boardman, K. C. Podratz, E. A. Perez, and N. J. Maihle A Preliminary Study of Serum Concentrations of Soluble Epidermal Growth Factor Receptor (sErbB1), Gonadotropins, and Steroid Hormones in Healthy Men and Women
Cancer Epidemiol. Biomarkers Prev.,
November 1, 2001;
10(11):
1175 - 1185.
[Abstract][Full Text][PDF]
T. Sandberg, A. Ehinger, and B. Casslén Paracrine Stimulation of Capillary Endothelial Cell Migration by Endometrial Tissue Involves Epidermal Growth Factor and Is Mediated Via Up-Regulation of the Urokinase Plasminogen Activator Receptor
J. Clin. Endocrinol. Metab.,
April 1, 2001;
86(4):
1724 - 1730.
[Abstract][Full Text]
B. Moller, C. Rasmussen, B. Lindblom, and M. Olovsson Expression of the angiogenic growth factors VEGF, FGF-2, EGF and their receptors in normal human endometrium during the menstrual cycle
Mol. Hum. Reprod.,
January 1, 2001;
7(1):
65 - 72.
[Abstract][Full Text][PDF]
S. Scotti, P.-A. Regidor, A.E. Schindler, and E. Winterhager Reduced proliferation and cell adhesion in endometriosis
Mol. Hum. Reprod.,
July 1, 2000;
6(7):
610 - 617.
[Abstract][Full Text][PDF]
